ArticlePloS one2026
Unimodal vs. multimodal deep learning for non-invasive MGMT promoter methylation prediction in glioblastoma: A systematic evaluation on the BraTS 2021 dataset.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults, with a median survival of 14.6 months under standard radiotherapy and temozolomide (TMZ) chemotherapy. The methylation status of the O⁶-methylguanine-DNA methyltransferase (MGMT) promoter is a critical biomarker predicting TMZ response; however, its determination currently requires invasive tissue sampling. Non-invasive prediction of MGMT promoter methylation from multiparametric MRI (mpMRI) through deep learning represents a compelling alternative, yet its clinical feasibility remains unresolved. Using the BraTS 2021 dataset (582 patients, four MRI sequences: FLAIR, T1w, T1wCE, T2w), we conducted a systematic comparative study of unimodal and multimodal deep learning approaches based on VGG-16, exploring 1,380 experimental configurations (unimodal: 192; multimodal: 1,188) across three imaging planes, eight slice counts, and three multimodal fusion strategies (early, intermediate, and late fusion). In the unimodal setting, the best model trained on T2w coronal images (32 slices, no transfer learning) achieved an accuracy of 0.6458 and an AUC of 0.6422 on the validation set, but dropped to 0.5586 and 0.5533 on the independent test set, revealing substantial overfitting attributable to limited dataset size. Strikingly, multimodal fusion consistently failed to outperform the best unimodal model, with all three fusion strategies plateauing at ~0.64 accuracy and ~0.64 AUC on validation data. Transfer learning improved generalization across train/test distributions at the cost of peak performance. These findings suggest, for the tested framework in this study, that MGMT methylation status prediction from mpMRI remains fundamentally constrained by dataset heterogeneity and size, irrespective of modality combination strategy, and that T2w coronal acquisitions could be more interesting in future data collection efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.